Tables

TABLE 1 TOP ACQUISITIONS IN CARDIOVASCULAR INDUSTRY 12
TABLE 1 CARDIOVASCULAR DRUGS MARKET REVENUE BY TYPES' 2017-2024 ($BILLION) 31
TABLE 2 CARDIOVASCULAR DRUGS MARKET REVENUE BY REGIONS' 2017-2024 ($BILLION) 39
TABLE 3 NOVARTIS AG: OFFERINGS 50
TABLE 4 NOVARTIS AG: RECENT DEVELOPMENTS 50
TABLE 5 SANOFI: OFFERINGS 57
TABLE 6 SANOFI: RECENT DEVELOPMENTS 58
TABLE 7 BAYER AG: OFFERINGS 62
TABLE 8 BAYER AG: RECENT DEVELOPMENTS 62
TABLE 9 JOHNSON & JOHNSON: PRODUCT OFFERINGS 67
TABLE 10 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 67
TABLE 11 ASTRA ZENCA PLC: OFFERINGS 74
TABLE 12 ASTRA ZENCA PLC: RECENT DEVELOPMENTS 74
TABLE 13 DAIICHI SANKYO' INC.: RECENT DEVELOPMENTS 80
TABLE 14 BRISTOL-MYERS SQUIBB.: RECENT DEVELOPMENTS 81
TABLE 15 BRISTOL-MYERS SQUIBB.: KEY DEVELOPMENTS 81
TABLE 16 GLAXOSMITHKLINE PLC.: OVERVIEW 83
TABLE 17 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 84
TABLE 18 UNITED THERAPEUTICS CORP.: OVERVIEW 85
TABLE 19 SUN PHARMACEUTICALS: OVERVIEW 86
TABLE 20 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS 87
TABLE 21 TAKEDA PHARMACEUTICAL CO' LTD.: OVERVIEW 88
TABLE 22 BOEHRINGER INGELHEIM GMBH: OVERVIEW 89
TABLE 23 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS 89
TABLE 24 GILEAD SCIENCES' INC.: OVERVIEW 91

?

LIST OF FIGURE

Charts

CHART 1 GLOBAL CARDIOVASCULAR DISEASE MARKET 2017 ($BILLION) 12
CHART 2 RESEARCH METHODOLOGY OF GLOBAL CARDIOVASCULAR DRUGS MARKET 15
CHART 3 GLOBAL CARDIOVASCULAR DRUGS MARKET REVENUE' 2017-2024 ($BILLION) 17
CHART 4 NUMBER OF CARDIOVASCULAR DRUGS APPROVED FROM 2011-2016 21
CHART 5 SEGMENTATION OF GLOBAL CARDIOVASCULAR DRUGS MARKET 21
CHART 6 PORTER 5 FORCES OF CARDIOVASCULAR DRUGS MARKET 22
CHART 7 PEST ANALYSIS OF CARDIOVASCULAR DRUGS MARKET 23
CHART 8 MARKET DYNAMICS - DRO ANALYSIS 24
CHART 9 WORLD POPULATION AGED 65 YEARS AND ABOVE' 1960-2060 (%) 25
CHART 10 DRO - IMPACT ANALYSIS OF GLOBAL CARDIOVASCULAR DRUGS MARKET 28
CHART 11 KEY STAKEHOLDERS 29
CHART 12 CARDIOVSCULAR DRUGS MARKET BY PRODUCT TYPE SEGMENTATION' 2017-2024 ($BILLION) 30
CHART 13 ANTI-HYPERTENSIVES CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION' 2017-2024 ($BILLION) 32
CHART 14 ANTI-HYPERLIPIDEMICS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION' 2017-2024 ($BILLION) 33
CHART 15 ANTI-COAGULANTS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION' 2017-2024 ($BILLION) 34
CHART 16 ANTI-ARRHYTHMIC CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION' 2017-2024 ($BILLION) 34
CHART 17 OTHERS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION' 2017-2024 ($BILLION) 35
CHART 18 CARDIOVASCULAR DISEASES PREVALENCE WORLDWIDE IN MILLIONS (2015) 38
CHART 19 CARDIOVACULAR DRUGS MARKET BY REGIONAL SEGMENTATION' 2017 VS 2024 (%) 38
CHART 20 CARDIOVASCULAR DRUGS MARKET REVENUE IN NORTH AMERICA' 2017-2024 ($BILLION) 39
CHART 21 CARDIOVASCULAR DRUGS MARKET REVENUE IN THE EUROPE REGION' 2017-2023 ($BILLION) 41
CHART 22 TYPE OF MEDICATION USED BY ADULTS WITH CARDIOVASCULAR DISEASE IN THE UK IN 2014 43
CHART 23 CARDIOVASCULAR DRUGS MARKET REVENUE IN THE APAC REGION' 2017-2023 ($BILLION) 45
CHART 24 CARDIOVASCULAR DRUGS MARKET REVENUE IN REST OF THE WORLD' 2017-2023 ($BILLION) 46
CHART 25 NOVARTIS AG: OVERVIEW SNAPSHOT 52
CHART 26 NOVARTIS AG: BUSINESS UNITS 53
CHART 27 NOVARTIS GA: GEOGRAPHICAL PRESENCE 54
CHART 28 NOVARTIS AG: SWOT ANALYSIS 55
CHART 29 SANOFI SA: OVERVIEW SNAPSHOT 58
CHART 30 SANOFI SA: SEGMENTATION 59
CHART 31 SANOFI SA: GEOGRAPHIC REVENUE 60
CHART 32 SANOFI SA: SWOT ANALYSIS 61
CHART 33 BAYER AG: OVERVIEW SNAPSHOT 63
CHART 34 BAYER AG: BUSINESS UNITS 64
CHART 35 BAYER GA: GEOGRAPHICAL PRESENCE 65
CHART 36 BAYER AG: SWOT ANALYSIS 66
CHART 37 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 69
CHART 38 JOHNSON & JOHNSON: BUSINESS UNITS 70
CHART 39 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 71
CHART 40 JOHNSON & JOHNSON: SWOT ANALYSIS 73
CHART 41 ASTRA ZENCA PLC: OVERVIEW SNAPSHOT 75
CHART 42 ASTRA ZENCA PLC: BUSINESS UNITS 77
CHART 43 ASTRA ZENCA PLC: GEOGRAPHIC PRESENCE 78
CHART 44 ASTRA ZENCA PLC: SWOT ANALYSIS 78